MAM
What if, asks Kyoorius Designyatra
MUMBAI: All great things are achieved by making that extra effort. Kyoorius Designyatra, in its ninth year, will explore what it takes to create something new and unprecedented.
The annual conferences on creativity, themed ‘What if?’ will bring together speakers from around the world who redefine conventions and use radical approaches that push people to think beyond clichés. Where others see risks and obstacles, they see opportunities.
Kyoorius founder and CEO Rajesh Kejriwal said, “If you are looking to discuss the latest trends in digital, design and brand strategy or simply expose yourself to the most radical thinkers today, Designyatra is the platform to do just that. Here the barriers between young and old, senior and junior are dissolved, and interaction between designers, marketers, brands as well as young professionals and students, is welcomed and encouraged.”
The event will be held from 11 to 13 September and will be attended by 1300 delegates over three days at the Grand Hyatt in Goa. Kyoorius Designyatra brings radical and divergent ideas into focus through formats ranging from talks and workshops, breakout sessions to portfolio reviews, allowing the audience multiple levels of interaction.
Speakers will curate talks keeping in mind the Indian context.
IAA Kyoorius Digiyatra will look at the latest in digital – discovering new ways to realise its potential as a marketing and communication tool for India’s mobile audiences. An entire day will be dedicated to deconstructing the newest technological innovations, decoding online marketing, exploring content strategy for consumer engagement and ways to humanise digital.
Kyoorius Designyatra will engage in stimulating discussions, creative collaborations and interactions. Designyatra offers the opportunity to expand professional networks, meet the most innovative entrepreneurs and mingle with industry professionals.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
